Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market By Clinical Causes (Inflammatory Disease, Neurotrophic Keratitis (NK), Epithelial/Limbal Stem Cell Deficiency, Others) By Type (Device, Medication) By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) By End User (Hospitals, Home-care, Specialty Clinics, Others)- Growth, Share, Opportunities & Competitive Analysis, 2016 – 2028

How do the Neoantigen-Based Personalized Cancer Therapeutic Vaccines work?

Cancer vaccines induce an immune response in the body by using weakened or killed viruses, bacteria, or other infection-causing agents. Cancer is the leading cause of death in the world, accounting for nearly 10 million deaths in 2020, or almost one in every six.

Breast, lung, colon, rectum, and prostate cancers are the most common. Companies, universities, and associations are collaborating to assess challenges and identify opportunities in the research and development of Neoantigen-based Personalized Cancer Therapeutic Vaccines. These vaccines work similarly, with the immune system recognizing, attacking, and destroying cancer cells.

Neoantigens derived from cancer-specific mutations are another appealing class of antigens for therapeutic cancer vaccines. Vaccination against tumor-specific neoantigens reduces the risk of induction of central and peripheral tolerance and autoimmunity. Neoantigen-based cancer vaccines have recently demonstrated significant therapeutic potential in preclinical and early-phase clinical trials.

Tumor-specific antigens, also known as neoantigens, are not found in normal cells and are derived from random somatic mutations in tumor cells.

These Neoantigen-based Personalized Cancer Therapeutic Vaccines, which are being developed based on novel technology platforms approaches, will help advance precision medicine by providing feasible tools for analyzing the mutation antigen profile, gene signature, and epigenetic modification of tumor and immune cells, as well as the magnitude, homing capacity, cytotoxic function, and T cell receptor (TCR) repertoire of T lymphocytes.

neoantigen-based-personalized-cancer-therapeutic-vaccines-market

What is the Market Size of Neoantigen-Based Personalized Cancer Therapeutic Vaccines in terms of value?


The global Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market is projected to increase at a significant CAGR of XX% in the coming years. In 2021, the global Neoantigen-Based Personalized Cancer Therapeutic Vaccines market was valued at USD XX billion and projected to reach USD XX billion by 2028.

The demand for Neoantigen-Based Personalized Cancer Therapeutic Vaccines is projected to increase substantially in the coming years and is presumed to generate revenue opportunities for the key industry players worth USD XX billion during the forecast period of 2022 and 2028. 

What are the key emerging vaccines for Neoantigen-Based Personalized Cancer Therapeutic Vaccines?


GEN-009 Adjuvanted Vaccine: Genocea Biosciences-

GEN-009 is a personalized cancer vaccine that optimizes target selection using Genocea's proprietary ATLAS platform, giving the vaccine the best chance of targeting the right tumor mutations in each person.

Tedopi (OSE2101): OSE Immunotherapeutics

Tedopi, neoantigen-based immunotherapy in development for the treatment of HLA-A2+ NSCLC, is SE Immunotherapeutics' lead clinical immune-oncology asset. It combines ten optimized neo-epitopes and protein fragments that structurally alter cancer cells and activate strong immune responses against them.

TG01 Vaccine: Targovax

Targovax is developing TG01, a Neoantigen-specific peptide vaccine that targets AS mutations that cause uncontrolled cell divisions in solid tumors. It has created a one-of-a-kind vaccine against mutant RAS.

NEO-PV-01: Neon Therapeutics

NEO-PV-01 is a fully personalized cancer vaccine that targets neoantigens that are individually designed and manufactured for each patient based on the tumor's unique mutational fingerprint.

Interesting Facts about Neoantigen-Based Personalized Cancer Therapeutic Vaccines Industry

  • The Neoantigen-Based Personalized Cancer Therapeutic Vaccines market has been primarily attributed to significant market drivers such as rising cancer prevalence, increasing adoption of personalized medicine to tailor patient treatment on an individual level, and significant external funding for research and development exercises.
  • North America region had a considerable share in volume and value in the global Neoantigen-Based Personalized Cancer Therapeutic Vaccines market in 2021 and is projected to continue its dominance over the forecast period.
  • According to vaccine Route of Administrations, neo-antigen based mRNA vaccines, neo-antigen based Viral/Bacterial vaccines, neo-antigen based polypeptide vaccines, neo-antigen based Dendritic cell vaccines, immunotherapy-based vaccines, and allogeneic and autologous tumor cell based neo-antigen vaccines will be available.
  • Companies, universities, and associations collaborate to assess challenges and identify opportunities for Neoantigen-based Personalized Cancer Therapeutic Vaccines R&D.

Who are the Top 10 players/companies in the Neoantigen-Based Personalized Cancer Therapeutic Vaccines market regarding value?

The key players in the global Neoantigen-Based Personalized Cancer Therapeutic Vaccines market in terms of value include NEC Corporation, BrightPath therapeutics, CUREVAC N.V., Geneos Therapeutics, Vaccibody, Transgene, Neon Therapeutic, Genocea Biosciences, Moderna, Advaxis, AstraZeneca, Gritstone Oncology, Inc., Incyte Corporation, Hangzhou Neoantigen Therapeutics, and Frame Pharmaceuticals.

These key players are concentrating on new product developments as well as technological innovation to enhance their production of Neoantigen-Based Personalized Cancer Therapeutic Vaccines to gain competitive market share at a global level. For instance, OSE Immunotherapeutics, which is developing the Tedopi (OSE2101) neoantigen cancer vaccine, is set to launch in 2022.

Tedopi (OSE2101) is a drug used to treat patients with HLA-A2+ non-small cell lung cancer (NSCLC). The vaccine is currently in phase III of clinical development.

On the other hand, BioNTech SE is a German company that manufactures neoantigen vaccines. Individualized Vaccines Against Cancer (IVAC) Mutanome platform developed by BioNTech SE engineers RNA molecules to produce customized neoantigen vaccine.

IVAC clinical trials for triple-negative breast cancer, multiple tumor Route of Administrations, and melanoma are currently underway.

Who are the Top 10 Countries in the Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market?

The major countries in the global Neoantigen-Based Personalized Cancer Therapeutic Vaccines market are the US, Canada, China, Japan, Australia, Germany, France, Italy, Spain, and the UK. The largest market share is in the United States.

In the United States, in 2019, 1,752,735 new cancer cases were reported, and 599,589 cancer deaths were reported. Four hundred thirty-nine new cancer cases were reported for every 100,000, and 146 died from cancer. However, increased funding for research and development activities in the United States is helping propel the global neoantigen cancer vaccine market forward.

Neon Therapeutics, a US-based company, launched NEO-PV-01, which is a fully personalized cancer vaccine that targets neoantigens that are custom-designed and manufactured for each patient based on the tumor's unique mutational fingerprint. NEO-neoantigen-targeting PV-01 peptides elicit an antitumor immune response that directs patients' T-cells to target and kill cancer cells.

Multiple phases I clinical trials for Urinary Bladder Cancer, Non-small Cell Lung Cancer, and Metastatic Melanoma are currently underway. Similarly, Agenus Inc. created the AutoSynVax (ASV) neoantigen vaccine, which is used in conjunction with the adjuvant QS-21 Stimulon to treat solid tumors. ASV is currently in Phase 1 clinical trials in the United States.

Which is the Key molecule Route of Administration segment in the Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market?

Gene therapy is expected to grow at a substantial rate in the neoantigen-based personalized cancer therapeutic vaccine market over the forecast period. Gene therapy is a medical field that focuses on genetically altering cells to provide a therapeutic effect or to heal disease by repairing or reconstructing damaged genetic material.

The goal of gene therapy is to address a congenital illness at its root. If, for instance, a mutation in a specific gene results in the production of a dysfunctional protein, resulting (usually recessively) in inherited disease, gene therapy could be used to deliver a copy of this gene that does not contain the deleterious mutation, resulting in the production of a functional protein. This method is known as gene replacement therapy and is used to treat inherited retinal disorders.

What are the Major Driving Factors for the Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market?

The Neoantigen-Based Personalized Cancer Therapeutic Vaccines have expanded primarily due to significant market drivers such as rising cancer prevalence, increased adoption of personalized medicine to tailor patient treatment on an individual level, and significant external funding for research and development.

Rapid technological advancements and infrastructure developments in the healthcare sector, on the other hand, are propelling the Neoantigen-Based Personalized Cancer Therapeutic Vaccines market forward. Furthermore, rising investments by governments and healthcare providers are expected to drive the global neoantigen cancer vaccine market in the coming years.

In addition, growing awareness of the unmet need for adjuvant therapies and incremental healthcare spending around the world is also expected to increase market size and allow vaccine manufacturers to penetrate further into the market.

What are the Major Restraints for the Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market?

Higher cost of personalized cancer vaccines, challenges in clinical development and optimization process, and uncertain reimbursement scenarios are the major restraint factors in Neoantigen-Based Personalized Cancer Therapeutic Vaccines market growth. In addition, payer uncertainty, outcome-based pricing, and high capital requirements are also impeding global Neoantigen-Based Personalized Cancer Therapeutic Vaccines market expansion.

Which Region Dominated the World Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market?

In 2021, North America will dominate the Neoantigen-Based Personalized Cancer Therapeutic Vaccines market over the forecast period due to the prevalence of advanced healthcare infrastructure and rising cancer incidences.

A total of 1.9 million cancer cases were reported in North America. Breast (14 percent), lung (13 percent), prostate (12 percent), colorectum (10 percent), bladder (5 percent), non-Hodgkin lymphoma (4 percent), melanoma of the skin (4 percent), and other cancers are the most common (38 percent ). An estimated 693,000 people died from cancer.

Rapid technological advancements and healthcare infrastructure developments, on the other hand, are propelling the Neoantigen-Based Personalized Cancer Therapeutic Vaccines market forward. Additionally, rising government and healthcare provider investments are expected to propel the global neoantigen cancer vaccine market in the coming years. Rising awareness of the unmet need for adjuvant therapies and increased healthcare spending globally is expected to increase market size and allow vaccine manufacturers to expand their market penetration.

The Asia Pacific is expected to have the highest growth rate and growth rate during the forecast period. This is due to rising healthcare infrastructure development costs and the growth and increased awareness of personalized cancer vaccines.

Growing government and healthcare provider investments are expected to drive the global neoantigen cancer vaccine market in the coming years. In addition, rising awareness of the unmet need for adjuvant therapies and increased healthcare spending globally are expected to increase market size and allow vaccine manufacturers to expand their market penetration.

Global Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market – By Drugs by the Route of Administration

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical

Global Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market – By Molecule Route of Administration

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

Frequently asked questions about the global Neoantigen-Based Personalized Cancer Therapeutic Vaccines industry

The global Neoantigen-Based Personalized Cancer Therapeutic Vaccines market is expected to be impacted significantly by COVID-19.

North America accounted for the highest share in the global Neoantigen-Based Personalized Cancer Therapeutic Vaccines market in terms of value.

The market for Neoantigen-Based Personalized Cancer Therapeutic Vaccines has grown primarily as a result of major market drivers such as rising cancer prevalence, increased adoption of personalised medicine to tailor patient treatment on an individual level, and significant external funding for R&D.

Subcutaneous segment had a major share in 2021 with more than 40% of the market revenue share.

Gene Therapy segment had a major share in 2021 with more than 30% of the market revenue share.

Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market Scope

Report Attribute Details
Market Value in 2021 USD XX billion
Market Value in 2028 USD XX billion
CAGR XX%
Benchmarking Year 2021
Past data 2016 – 2021
Forecast period 2022 – 2028
Choose License Type
Published Date:  Jul 2022
Category:  Medical Devices
Report ID:   60580
Report Format:   PDF
Pages:   185
Rating:    4.9 (13)
Connect With Us
+1-408-641-3282
24/7 Research Support